Noor Giesbertz

Dr. Noor Giesbertz


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2013 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
NGNoor Giesbertz
Noor Giesbertz
ABAnnelien L Bredenoord
Annelien L Bredenoord
JDJohannes J M van Delden
Johannes J M van Delden
Assent is a relatively young term in research ethics, but became an often mentioned ethical requirement in current pediatric research guidelines. Also, the European Society of Human Genetics considers assent an important condition for the inclusion of children in biobanks. However, although many emphasize the importance of assent, few explain how they understand the concept and few have elaborated on the underlying grounds. In this paper, we will discuss the different underlying ethical principles of assent. In the first category, assent appears to be derived from informed consent. This understanding is grounded in respect for autonomy and protection against harm. We conclude that this interpretation of assent is not of added value as a majority of children cannot be considered competent to make autonomous decisions. In addition, other safeguards are more appropriate to protect children against harm. The grounds from the second category can be classified as engagement grounds. These grounds do justice to the specifics of childhood and are of added value. Furthermore, we argue that it follows that both the content and the process of assent should be adjusted to the individual child. This can be referred to as personalized assent. Personalized assent is an appeal to the moral responsibility and integrity of the researcher.

7 August 2012 in PLOS Biology
Verified
Journal Article
Open access
PDF file
NGNoor Giesbertz
Noor Giesbertz
ABAnnelien L. Bredenoord
Annelien L. Bredenoord
JDJohannes J. M. van Delden
Johannes J. M. van Delden
Residual samples are an important source of tissue for biobanks. They refer to leftover tissue that is obtained in the course of clinical care. Residual samples can be included through an opt-in method—that is, a person explicitly expresses consent to include residual tissue—or an opt-out method—that is, the tissue is stored unless a person explicitly refuses. At the moment there is a renewed interest in the appropriate method for the inclusion of residual samples in biobanks. The expansion of biobanks and rapid developments in biomedical research underscore the need to evaluate the proper procedure. In this article we revisit the arguments in favor and against opt-in and opt-out methods for residual tissue research. We conclude firstly that an opt-out method is only justifiable when certain conditions are met: (1) awareness has to be raised, (2) sufficient information has to be provided, and (3) a genuine possibility to object has to be offered. An opt-out procedure that fulfills these conditions can be called a “thick” opt-out method. As a consequence, the dichotomy between opt-in and opt-out is less stark than usually suggested, as both methods require a certain amount of effort. Secondly, we conclude that because of the diversity of tissue and research, not every situation can be treated alike. There are at least four situations that require opt-in procedures: (1) research with higher risks or increased burdens, (2) the use of controversial or high-impact techniques, (3) research on sensitive tissue types, and (4) research involving vulnerable patients. We suggest that further interdisciplinary debate should answer the question when to opt-in or when to opt-out.

1 June 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
SDSerwet Demirdas
Serwet Demirdas
LBLisa M. van Den Bersselaar
Lisa M. van Den Bersselaar
RLRosan Lechner
Rosan Lechner
JBJessica Bos
Jessica Bos
SASuzanne I.M. Alsters
Suzanne I.M. Alsters
AHArjun C. Houweling
Arjun C. Houweling
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a rare connective tissue disorder with a high risk for arterial, bowel, and uterine rupture, caused by heterozygous pathogenic variants in COL3A1 . The aim of this cohort study is to provide further insights into the natural history of vEDS and describe genotype-phenotype correlations in a Dutch multicenter cohort to optimize patient care and increase awareness of the disease. METHODS: Individuals with vEDS throughout the Netherlands were included. The phenotype was charted by retrospective analysis of molecular and clinical data, combined with a one-time physical examination. RESULTS: A total of 142 individuals (50% female) participated the study, including 46 index patients (32%). The overall median age at genetic diagnosis was 41.0 years. More than half of the index patients (54.3%) and relatives (53.1%) had a physical appearance highly suggestive of vEDS. In these individuals, major events were not more frequent ( P =0.90), but occurred at a younger age ( P =0.01). A major event occurred more often and at a younger age in men compared with women ( P <0.001 and P =0.004, respectively). Aortic aneurysms ( P =0.003) and pneumothoraces ( P =0.029) were more frequent in men. Aortic dissection was more frequent in individuals with a COL3A1 variant in the first quarter of the collagen helical domain ( P =0.03). CONCLUSIONS: Male sex, type and location of the COL3A1 variant, and physical appearance highly suggestive of vEDS are risk factors for the occurrence and early age of onset of major events. This national multicenter cohort study of Dutch individuals with vEDS provides a valuable basis for improving guidelines for the diagnosing, follow-up, and treatment of individuals with vEDS.

1 April 2019 in Nature Reviews Genetics
Verified
Journal Article
Closed access
NGNoor Giesbertz
Noor Giesbertz
WHWim H. van Harten
Wim H. van Harten
ABAnnelien L. Bredenoord
Annelien L. Bredenoord

16 February 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
NGNoor Giesbertz
Noor Giesbertz
ABAnnelien L. Bredenoord
Annelien L. Bredenoord
JDJohannes J. M. van Delden
Johannes J. M. van Delden
Noor Giesbertz and colleagues consider different re-contact policy designs that could be used by biobanks to obtain permission for the continued use of samples collected from children.

20 March 2013 in The American Journal of Bioethics
Verified
Journal Article
Closed access
NGNoor Giesbertz
Noor Giesbertz
ABAnnelien L. Bredenoord
Annelien L. Bredenoord
JDJohannes J. M. van Delden
Johannes J. M. van Delden
(2013). A Thick Opt-Out Is Often Sufficient. The American Journal of Bioethics: Vol. 13, No. 4, pp. 44-46.